OBJECTIVES:: Little evidence is available on the management of patients with Advanced Gastric Cancer (AGC) after failure of 1st-line treatment. This study presents real-world data on patient characteristics and treatment patterns for these patients in Colombia.  METHODS:: Eligible patients were ≥18 years old, diagnosed with unresectable or metastatic GC, between January 2009 and June 2016, had received 1st-line chemotherapy treatment, had ≥3 months of follow-up after 1st-line discontinuation, and had not participated in a clinical trial. Data were obtained from the clinical charts of the patients, Data were summarized using descriptive statistics.  RESULTS:: This preliminary report includes 36 patients. Mean age was 61.4 (SD 10.2) years and 63.9% of patients were male; 55.6% and 16.7% progressed to second and third-line therapies, respectively. ECOG performance status (PS) at diagnosis of MGC was PS=0 in 13.9%, PS=1 in 66.7%, PS=2 in 16.7%, and PS=3 in 2.8%. Prior to initiation 2º line, it was PS=0 in 0%, PS=1 in 75%, and PS=2 in 20%. Thirteen different regimens were used as 1st- and twelve in 2nd-line treatments. Fluorouracil+Leucovorin (10; 27.8%), and Fluorouracil+Cisplatin (9; 25%) were the most frequent 1st-line regimens, while Capecitabine (5; 25%), Capecitabine+Oxaliplatin (3; 15%) and Irinotecan (3; 15%) prevailed in 2nd-line treatment. Most of patients (80.6%) were hospitalized at any time after the diagnosis of unresectable or metastatic GC. CONCLUSIONS:: Treatment patterns for patients with AGC in Colombian institutions are highly heterogeneous. The results of this study may contribute to the development of new strategies and guidelines for AGC management in Colombia.